{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:02:32Z","timestamp":1790906552026,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the field of oncofertility, patients with breast cancer are often administered letrozole as an adjuvant drug before and after oocyte retrieval to prevent an increase in circulating estradiol.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report a case of abdominal hemorrhage due to an ovarian rupture in a 29-year-old Japanese patient who restarted letrozole 2\u00a0days after an oocyte retrieval procedure in which 14 mature oocytes were retrieved. The patient had sought embryo cryopreservation as a fertility preservation option before undergoing treatment for recurrent breast cancer. A day after restarting letrozole treatment, the patient unexpectedly developed severe abdominal pain. Laparoscopic hemostasis was performed to manage the ovarian swelling and hemorrhage.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The ovaries can be restimulated by restart letrozole after an oocyte retrieval procedure. Therefore, reproductive-medicine practitioners should understand the potential complications of letrozole administration in such cases and take steps to ensure that they are minimized.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-021-02938-8","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T23:04:23Z","timestamp":1624748663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Severe hemoperitoneum resulting from restart of letrozole after oocyte retrieval procedure: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Haipeng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Samejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Gomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Itaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosihisa","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigetaka","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,27]]},"reference":[{"key":"2938_CR1","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jama.2013.776","volume":"309","author":"RH Johnson","year":"2013","unstructured":"Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA. 2013;309:800\u20135.","journal-title":"JAMA"},{"key":"2938_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10549-012-2031-7","volume":"134","author":"DF Merlo","year":"2012","unstructured":"Merlo DF, Ceppi M, Filiberti R, Bocchini V, Znaor A, Gamulin M, et\u00a0al. Breast cancer incidence trends in European women aged 20\u201339 years at diagnosis. Breast Cancer Res Treat. 2012;134:363\u201370.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"2938_CR3","first-page":"846","volume":"31","author":"M Kasum","year":"2015","unstructured":"Kasum M, von Wolff M, Franulic D, \u010cehi\u0107 E, Klepac-Pulani\u0107 T, Ore\u0161kovi\u0107 S, et\u00a0al. Fertility preservation options in breast cancer patients. Gynecol Endocrinol. 2015;31(11):846\u201351.","journal-title":"Gynecol Endocrinol"},{"key":"2938_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/humrep\/dex027","volume":"32","author":"RJ Rodgers","year":"2017","unstructured":"Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M, et\u00a0al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017;32:1033\u201345.","journal-title":"Hum Reprod"},{"key":"2938_CR5","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1210\/jc.2006-0962","volume":"91","author":"K Oktay","year":"2006","unstructured":"Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et\u00a0al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91:3885\u201390.","journal-title":"J Clin Endocrinol Metab"},{"key":"2938_CR6","first-page":"9","volume":"55","author":"ZX Cheng","year":"2020","unstructured":"Cheng ZX, Kong G, Zhang CL, Zhao YN. Letrozole versus gonadotropin-releasing hormone antagonist during luteal phase in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial. Zhonghua Fu Chan Ke Za Zhi. 2020;55:9\u201314.","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"2938_CR7","first-page":"106","volume":"1","author":"Y Kuang","year":"2013","unstructured":"Kuang Y, Chen Q, Hong Q, Lyu Q, Fu Y, Ai A, et\u00a0al. Luteal-phase ovarian stimulation case report: three-year follow-up of a twin birth. J Fertiliz. 2013;1:106.","journal-title":"J Fertiliz."},{"issue":"1","key":"2938_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.rbmo.2020.09.001","volume":"42","author":"K Kuroda","year":"2021","unstructured":"Kuroda K, Nagai S, Ikemoto Y, Matsumura Y, Ochiai A, Nojiri S, et\u00a0al. Incidences and risk factors of moderate-to-severe ovarian hyperstimulation syndrome and severe hemoperitoneum in 1,435,108 oocyte retrievals. Reprod Biomed Online. 2021;42(1):125\u201332.","journal-title":"Reprod Biomed Online"},{"issue":"6","key":"2938_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.rbmo.2014.08.008","volume":"29","author":"K Nouri","year":"2014","unstructured":"Nouri K, Walch K, Promberger R, Kurz C, Tempfer CB, Ott J. Severe haematoperitoneum caused by ovarian bleeding after transvaginal oocyte retrieval: a retrospective analysis and systematic literature review. Reprod Biomed Online. 2014;29(6):699\u2013707.","journal-title":"Reprod Biomed Online"},{"key":"2938_CR10","doi-asserted-by":"publisher","first-page":"101643","DOI":"10.1016\/j.jogoh.2019.101643","volume":"49","author":"R Tshzmachyan","year":"2020","unstructured":"Tshzmachyan R, Hambartsoumian E. The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study. J Gynecol Obstet Hum Reprod. 2020;49:101643.","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2938_CR11","first-page":"8528","volume":"11","author":"MS Kamath","year":"2017","unstructured":"Kamath MS, Maheshwari A, Bhattacharya S, Lor KY, Gibreel A. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation. Cochrane Database Syst Rev. 2017;11:8528.","journal-title":"Cochrane Database Syst Rev."},{"key":"2938_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ajog.2016.08.018","volume":"216","author":"Q Mai","year":"2017","unstructured":"Mai Q, Hu X, Yang G, Luo Y, Huang K, Yuan Y, et\u00a0al. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial. Am J Obstet Gynecol. 2017;216:42.","journal-title":"Am J Obstet Gynecol"},{"key":"2938_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12958-018-0367-5","volume":"16","author":"J Haas","year":"2018","unstructured":"Haas J, Bassil R, Gonen N, Meriano J, Jurisicova A, Casper RF. The VEGF and PEDF levels in the follicular fluid of patients co- treated with LETROZOLE and gonadotropins during the stimulation cycle. Reprod Biol Endocrinol. 2018;16:54.","journal-title":"Reprod Biol Endocrinol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02938-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-02938-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02938-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T23:11:47Z","timestamp":1624749107000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02938-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,27]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2938"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02938-8","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,27]]},"assertion":[{"value":"26 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived by the ethical committee of Saitama Medical University, Saitama Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient to publish this case report and any accompanying images. A copy of the written consent is available for review from the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HH, YT, KS, YG, TN, SI, YI, YO, SM, MS, and HS declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"327"}}